"Sao Paulo-Minas Gerais Center for Chagas Disease Treatment (SaMiTrop)"

摘要 恰加斯病(CD)仍然是世界上最被忽视的疾病之一，估计有5.7 拉丁美洲和中美洲有100万感染者。目前，CD患者存在许多障碍 必须克服才能获得诊断、适当的治疗和适当的随访。其中一个主要的原因是 漏诊率高，从而导致患者接受治疗。据估计，只有不到10%的患者 只有不到1%的人得到了诊断和治疗。此外，到目前为止，还没有“可靠”的方法来允许 测量治疗效果。在过去的15年里，来自S圣保罗-米纳斯吉拉斯热带地区的研究人员 医学研究中心(Sami-trop)开发了许多项目，证明了这一数字很高 在米纳斯吉拉斯州北部的流行区，除了提供有价值的 CD的自然病史、进展为心肌病的比率及其与 抗体水平。这类倡议成功的一大关键是它们与主要的 医疗保健，这使得有大量的患者陪伴超过10年成为可能。 因此，在这个项目中，它的目的是应用所有这些知识和表达来确定方法和 允许克服现有障碍的工具。所获得的结果将使增加这一数字成为可能 将为其提供治疗的确诊患者的数量，并确定实现这一目标的策略和生物标志物 有可能改善患者的随访，并帮助评估新的治疗方案。

ABSTRACT Chagas disease (CD) remains one of the most neglected illnesses in the world, with estimates indicating 5.7 million infected people in Latin and Central America. Currently, there are many barriers that patients with CD have to overcome to obtain a diagnosis, adequate treatment, and appropriate follow-up. One of the main ones is the high rate of underdiagnosis and consequently of patients treated. It is estimated that less than 10% of patients are diagnosed and that less than 1% are treated. Furthermore, to date, there is no "reliable" method that allows measuring therapeutic efficacy. During the last 15 years, researchers from the São Paulo-Minas Gerais Tropical Medicine Research Center (SaMi-Trop) have developed numerous projects that have evidenced the high number of patients in an endemic area in the north of the State of Minas Gerais, in addition to providing valuable information on the natural history of CD, the rate of progression to cardiomyopathy and its relationship with antibody levels. A great key to the success of such initiatives has been their strategic articulation with primary health care, which has made it possible to have large cohorts of patients accompanied for more than 10 years. Therefore, it is intended in this project to apply all this knowledge and articulation to identify methodologies and tools that allow overcoming existing barriers. The results obtained will make it possible to increase the number of diagnosed patients to whom treatment will be offered and identify strategies and biomarkers that make it possible to improve patient follow-up and help evaluate new treatment candidates.